Skip to main content
. 2016 Aug 3;7(37):59245–59259. doi: 10.18632/oncotarget.11043

Figure 6. FOXM1 knockdown enhances gefitinib sensitivity in vivo.

Figure 6

(A) Representative pictures of xenograft tumors are shown. (B) The tumor volumes were measured at the indicated time points. (C) Tumor weight derived from FOXM1-shRNA knockdown or control-shRNA knockdown was measured at day 28. (D–F) The expression levels of FOXM1, MET and pAKT were analyzed by qRT–PCR, western blotting and immunohistochemistry. Data are represented as means ± SD of each group. *P < 0.05, **P < 0.01, NS, nonsignificant, Student's t-test.